LIU Gui-mei,SUN Kun-liang,XIA Guang-rong.Treatment of 212 patients with limited-disease small cell lung cancer[J].Chinese Journal of Radiological Medicine and Protection,2008,28(4):381-385
Treatment of 212 patients with limited-disease small cell lung cancer
Received:April 24, 2008  
DOI:
KeyWords:Small cell lung carcinoma  Radiotherapy  Chemotherapy  Combined modality treatment  Prognosis
FundProject:
Author NameAffiliationE-mail
LIU Gui-mei Department of Radiation Oncology, Chest Hospital, Beijing 101149, China  
SUN Kun-liang Department of Radiation Oncology, Chest Hospital, Beijing 101149, China sunkl123@yahoo.cn 
XIA Guang-rong Department of Radiation Oncology, Chest Hospital, Beijing 101149, China  
Hits: 3037
Download times: 2127
Abstract::
      Objective To review the treatment effect of limited disease small cell lung cancer(LD-SCLC) and to evaluate the prognosis factors for SCLC.Methods From Aug. 2002 to Feb. 2006, 212 patients of SCLC confirmed with pathology and cytology were treated by combined modality. All patients were treated with chemotherapy 2_6 cycles, 59 patients of which were treated with only chemotherapy,108 patients of which were treated with chemotherapy plus radiotherapy, 45 patients of which were treated with surgery plus chemotherapy with or without radiotherapy. The patients of radiotherapy were exposed to 6 or 10 MV X-ray with a total dose of 40-66 Gy in 4-7 weeks.Results The overall median survival time was 15 months. The 1-,2- and 3-year overall survival rate were 58.0%, 33.2% and 22.1%,respectively.Univariate analysis indicated that weight loss, age, LDH,ECOG performance status, operation, response to radio-chemotherapy, cycles for chemotherapy, radiotherapy influenced survival significantly in LD_SCLC. Multivariate analysis suggested that ECOG performance status,response to therapy,cycles for chemotherapy were the independent prognostic factors for LD_SCLC.Conclusions For LD_SCLC patients, ECOG performance ≤1, good response to radio-chemotherapy, and ≥4 cycles chemotherapy show encouraging survival rate. Distance metastasis is still the mainstay of treatment failure.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:9058656  On-line:0

v
Scan QR Code
&et=90A12E02A57D426A6AF5264C4BFD773F3BD553E7065A24E09BED8BD2A0CBCB1B42EB413487E3FA2213B176408C6B57BF62CEC408FFFF54EB4558FCABD0E1C65404B6E5F0EA810284&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=67289AFF6305E306&aid=BDE938AEB2CA7D22BCC3E7152BD28514&vid=&iid=E158A972A605785F&sid=B9B90065CF5CD7F0&eid=44FDB9366EDDFA2B&fileno=20080422&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="67289AFF6305E306"; var my_aid="BDE938AEB2CA7D22BCC3E7152BD28514";